Population based study of mental disorders by nitric oxide system variants.
Description: Alanine:glyoxylate aminotransferase 2 (AGXT2; EC 2.6.1.44) is the only enzyme, which is capable of metabolizing R-form of 3-aminoisobutyrate. AGXT2 has another role of metabolizing asymmetric dimethylarginine (ADMA), which is a unique methyl amino acid that competitively inhibits nitric oxide synthase (NOS) family. AGXT2 activity is known to be regulated by four functional SNPs and the specific haplotype. (Dimethylarginine Dimethylaminohydrolase 1 (DDAH1; EC 3.5.3.18) also degrade ADMA. In this study, we investigated whether both the AGXT2 gene and the DDAH1 gene are associated with metabolic disease in 750 Japanese subjects recruited by complete enumeration survey method. The loss of AGXT2 function predicted by a SNP, rs16899974, and the haplotype were significantly correlated with the elevated blood pressure (p < 0.05) and casual blood sugar (p < 0.05), respectively as results of multiple regression. There were no association between the DDAH1 gene and these blood examinations.
Amount: ¥17,550,000
Funding type: research
Funder scheme: Grant-in-Aid for Scientific Research (B)
Start date: 2018-04-01
End date: 2021-03-31
Investigator: Shuichi Ueno
Institution: Ehime University
Funded outputs count: 15
Funder award ID: 18H02752
OpenAlex ID: G5294742893